PPT-CROI 2019: ARV for Prevention and Treatment, HIV Pathogenesis, and Cure

Joseph J Eron Jr MD Professor of Medicine University of North Carolina Chapel Hill North Carolina Financial Relationships With Commercial Entities Dr Eron has served as an ad hoc consultant to Janssen ViiV Healthcare Merck and Gilead Sciences Inc His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics ViiV Healthcare and Gilead Sciences Inc. 3 . G. olden Rules. Three golden rules to avoid dying from altitude illness:. Learn . the early symptoms of altitude illness and recognize when you have them. Remember, . there may . be . only one person . HHS Prevention Targets Pathogenesis Epidemiology Core Supplemental – Process–Outcome &#x/MCI; 0 ;&#x/MCI; 0 ;Background: Impact of CAUTI &#x/MCI; 1 ;&#x/MCI; 1 ;• & Nina Kim, MD . Associate Professor of Medicine. Division of Allergy & Infectious Diseases. University of Washington. No financial conflicts of interest. ION-4. Ledipasvir-Sofosbuvir. for 12 weeks. Tracking the HIV/AIDS epidemic in . Asia and the Pacific. Mr. J.V.R. Prasada Rao. UN Secretary General Special Envoy . on HIV/AIDS in Asia Pacific. 3 July 2013. Kuala Lumpur, Malaysia. . Jacques H. Grosset. Center for TB Research. Johns Hopkins School of Medicine. Why not from the bench to the bedside?. Because . I. t is how it began …for me (cough with blood…). It is how I became really interested in TB. New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD AIDS Research Consortium of Atlanta Follow me on Twitter @ drmt Financial Relationships With Commercial Entities Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Inflammatory Bowel Disease (IBD). Bowel Disorders. Colon Cancer. Rectal Cancer. Anal Cancer. Crohn’s Disease. Ulcerative Colitis. Incontinence. Diverticulitis. Fistula . Rectal Prolapse. Bowel Obstruction . Strategic Plan Working Group November 2019STRATEGIC PLAN FOR TRANSNIH RESEARCH TO CURE HEPATITIS B 1 Table of Contents Executive SummaryIntroductionStrategic Priority 1: Hepatitis B BiologyStrategi Résumé scientifique des principales études cliniques présentées à la CROI 2019. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Prediction. . of . events. . after. ART. initiation. INSTI . and IRIS ?. Test and . Treat. Same. Day. Switch DTG/ABC/3TC. to BIC/F/TAF. Miscellaneous. ART. Test and Treat the Same Day - Is this feasible ?. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Jeffrey Lennox, MD. Professor of Medicine. Emory University. Atlanta. , Georgia. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. AND OPPORTUNISTIC INFECTIONS. (CROI 2020). BOSTON| 8-11 MARCH 2020. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. This presentation is made in complete editorial freedom .